VIDEO: Increased visceral adipose tissue links to decreased IBD remission
Click Here to Manage Email Alerts
Higher visceral adipose tissue correlated with lower rates of inflammatory bowel disease remission among patients dosed with infliximab, vedolizumab or ustekinumab, according to Andres Yarur, MD, Medical College of Wisconsin.
“A significant amount of patients with Crohn's disease or ulcerative colitis experience partial or non-response to biologic therapy. This is explained by several things, some of them we know, some of them we do not,” Yarur said. “Identifying the variables that are associated with partial and non-response is important to improve the prognosis of our patients.”
In a prospective cohort study, researchers aimed to assess the association between baseline visceral adipose tissue (VAT) percentages, as well as other body composition parameters, with biologic response in patients with IBD. Study results showed visceral fat mass percentage played a significant role in steroid-free deep remission at week 14 in both univariate analysis (OR = 0.29; 95% CI, 0.14-0.59) as well as in multivariable analysis (adjusted OR = 0.34; 95% CI, 0.13-0.9).
“The big question here is what can we do to modify future randomized trials looking into interventions and seeing if reducing their VAT percentages influences their response to treatment,” Yarur concluded.
Collapse
Yarur A. Higher visceral adipose tissue is associated with lower rates of steroid-free deep and endoscopic remission in patients starting biologic therapy for inflammatory bowel diseases: results from the constellation study. Presented at: Digestive Disease Week; May 21-24, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts